VABILO na seminar "IDH1 and IDH2 mutations as friends and foes in human cancer", ki ga bo predstavil dr. Remco J. Molenaar, v petek 30.3.2018, ob 13.00 h, predavalnica B3, Biološko središče, Večna pot 111, Ljubljana
Vabilo na seminar / Invitation to Lecture
Dr. Remco J. Molenaar, MD Ph.D.
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Petek / Friday 30. 3. 2018, ob / at 13:00
Predavalnica B3 v Biološkem središču,
Lecture Hall B3 of the Biological Centre,
Večna pot 111, Ljubljana
The enzyme isocytrate dehydrogenase IDH is very important in carbohydrate metabolism, and when mutated in cancer cells, the metabolic pathway is drastically altered. Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including glioma, melanoma, prostate cancer and acute myeloid leukemia. Cancer patients with IDH1/2 mutations have a relatively prolonged survival compared with IDH1/2 wild-type counterparts. The underlying molecular mechanism in various subtypes of cancer have been demonstrated to also involve altered redox homeostasis and reduced DNA damage repair. Furthermore, the ongoing clinical trials in which we repurpose already-approved and off-patent drugs for the treatment of IDH1/2-mutated cancers will be discussed.
You are cordially invited to attend this lecture, which will be delivered in English.
Izr. prof. Matjaž Kuntner